Good evening and welcome to Markets Desk, your closing look at what moved markets today.
Moderna surged after the biotech raised its full-year revenue outlook, now projecting growth of as much as twenty-five percent heading into two thousand twenty-six. The market read that as a credibility signal — this is a company that had been fighting post-pandemic skepticism, and a forward guidance lift of that magnitude tends to bring buyers back in.
Turning to gold, Goldman Sachs has pushed out its bullish price target, and the reason is straightforward — the Federal Reserve's hawkish shift. When the cost of holding a non-yielding asset rises because rates stay higher for longer, the math on gold gets harder to defend. Goldman's message to clients: the trade isn't dead, but it's early, and patience is the position right now.
And HubSpot gave investors a sobering look at what AI caution is costing software companies. Small business customers are no longer buying on promise — they want to see AI tools perform on their own data before signing contracts. Chief Executive Yamini Rangan acknowledged the drag directly on the earnings call, and the market took note of just how much that proof-of-value threshold is slowing the sales cycle.
That's the tape. Markets Desk, signing off the floor.
